ReachMD Healthcare Image
Media formats available:
  • Overview

    Due to the absence of targeted therapies and the variable disease progression among patients, it’s difficult to predict outcomes and develop standard treatments for immunoglobulin A nephropathy (IgAN). Our experts, Drs. Annette Bruchfeld and Jonathan Barratt, discuss recent developments that shed light on potential therapeutic strategies and new mechanisms of action. Tune in to discover how you can achieve proteinuria remission and lower the risk of disease progression in your patients with IgAN.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Jonathan Barratt, PhD
    The Mayer Professor of Renal Medicine
    University of Leicester
    Leicester, United Kingdom

    Research: argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics, Visterra
    Consulting Fees: Alnylam, argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, Galapagos, Novartis, Omeros, Travere Therapeutics, Vera Therapeutics, Visterra

    Annette Bruchfeld, MD, PhD
    Professor of Nephrology
    Linköping University
    Linköping, Sweden

    Consulting Fees: AstraZeneca, Bayer, ChemoCentryx, Vifor Pharma
    Speaker´s honoraria: AbbVie, AstraZeneca, Fresenius, MSD, Vifor Pharma

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Tim Person has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Discuss the limitations of current treatments for patients with immunoglobulin A nephropathy (IgAN)
    • Review treatment approaches for IgAN 
    • Interpret the clinical relevance of clinical trial data on emerging therapies for patients with IgAN


  • Target Audience

    This activity is designed to meet the educational needs of nephrologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Creditsto UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.


  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.


  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free